The Bioavailability of the Novel Nonnucleoside Reverse Transcriptase Inhibitor GW420867X Is Unaffected by Food in Healthy Male Volunteers

Healthy Male Volunteers ◽

Male Volunteers ◽

Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers

Clinical Therapeutics ◽

10.1016/j.clinthera.2010.10.007 ◽

2010 ◽

Vol 32 (11) ◽

pp. 1889-1895 ◽

Cited By ~ 6

Author(s):

John Davis ◽

Frances Hackman ◽

Marie-Noella Ndongo ◽

HengWee Choo ◽

Drew Lewis ◽

...

Keyword(s):

Clinical Study ◽

Phase I ◽

Reverse Transcriptase ◽

Transcriptase Inhibitor ◽

Healthy Male ◽

Healthy Male Volunteers ◽

Male Volunteers ◽

Pharmacokinetics and Tolerability of GW420867X, a Nonnucleoside Reverse Transcriptase Inhibitor, following Single Escalating Doses in Healthy Male Volunteers

The Journal of Clinical Pharmacology ◽

10.1177/00912700122012706 ◽

2001 ◽

Vol 41 (10) ◽

pp. 1098-1105

Author(s):

Katy H. P. Moore ◽

Lindsey M. Cass ◽

Nigel Dallow ◽

Timothy C. Hardman ◽

Anne Jones ◽

...

Keyword(s):

Reverse Transcriptase ◽

Transcriptase Inhibitor ◽

Healthy Male ◽

Healthy Male Volunteers ◽

Male Volunteers ◽

Brain and CSF entry of the novel nonnucleoside reverse transcriptase inhibitor, GW420867X

Neuroreport ◽

10.1097/00001756-200011270-00043 ◽

2000 ◽

Vol 11 (17) ◽

pp. 3811-3815 ◽

Cited By ~ 2

Author(s):

Sarah Thomas ◽

Lindsey Cass ◽

William Prince ◽

Malcolm Segal

Keyword(s):

Reverse Transcriptase ◽

Transcriptase Inhibitor ◽

The Novel ◽

Initial highly-active antiretroviral therapy with a protease inhibitor versus a nonnucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect metaanalyses

Yearbook of Medicine ◽

10.1016/s0084-3873(08)70040-3 ◽

2007 ◽

Vol 2007 ◽

pp. 61-62

Author(s):

D.R. Snydman

Keyword(s):

Antiretroviral Therapy ◽

Protease Inhibitor ◽

Reverse Transcriptase ◽

Highly Active Antiretroviral Therapy ◽

Transcriptase Inhibitor ◽

Highly Active ◽

Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing nonnucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: openlabel randomised trial

Yearbook of Medicine ◽

10.1016/s0084-3873(08)70039-7 ◽

2007 ◽

Vol 2007 ◽

pp. 60-61

Author(s):

D.R. Snydman

Keyword(s):

Antiretroviral Therapy ◽

Protease Inhibitor ◽

Reverse Transcriptase ◽

Randomised Trial ◽

Transcriptase Inhibitor ◽

Faculty Opinions recommendation of Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1054717.506631 ◽

2006 ◽

Author(s):

Deanna Kroetz

Keyword(s):

Reverse Transcriptase ◽

Transcriptase Inhibitor ◽

Gene Variants ◽

Drug Transporter ◽

Enzyme Gene ◽

Metabolizing Enzyme ◽

Efavirenz Is a Potent Nonnucleoside Reverse Transcriptase Inhibitor of HIV Type 1 Replication in Microgliain Vitro

AIDS Research and Human Retroviruses ◽

10.1089/088922200750006056 ◽

2000 ◽

Vol 16 (15) ◽

pp. 1527-1537 ◽

Cited By ~ 9

Author(s):

Andrew V. Albright ◽

Susan Erickson-Viitanen ◽

Michael O'Connor ◽

Ian Frank ◽

Marlene M. Rayner ◽

...

Keyword(s):

Reverse Transcriptase ◽

Transcriptase Inhibitor ◽

Hiv Type 1 ◽

Drug Transporter and Metabolizing Enzyme Gene Variants and Nonnucleoside Reverse-Transcriptase Inhibitor Hepatotoxicity

Clinical Infectious Diseases ◽

10.1086/507101 ◽

2006 ◽

Vol 43 (6) ◽

pp. 779-782 ◽

Cited By ~ 68

Author(s):

M. D. Ritchie ◽

D. W. Haas ◽

A. A. Motsinger ◽

J. P. Donahue ◽

H. Erdem ◽

...

Keyword(s):

Reverse Transcriptase ◽

Transcriptase Inhibitor ◽

Gene Variants ◽

Drug Transporter ◽

Enzyme Gene ◽

Metabolizing Enzyme ◽

Bone mineral density, kidney function and participant‐reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir

HIV Medicine ◽

10.1111/hiv.13215 ◽

2021 ◽

Author(s):

Lucy Campbell ◽

Fowzia Ibrahim ◽

Birgit Barbini ◽

Amanda Samarawickrama ◽

Chloe Orkin ◽

...

Keyword(s):

Bone Mineral Density ◽

Reverse Transcriptase ◽

Kidney Function ◽

Outcome Measures ◽

Bone Mineral ◽

Transcriptase Inhibitor ◽

Mineral Density ◽

Risk Factors for Incident Diabetes in a Cohort Taking First-Line Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy

Medicine ◽

10.1097/md.0000000000002844 ◽

2016 ◽

Vol 95 (9) ◽

pp. e2844 ◽

Cited By ~ 24

Author(s):

Sumanth Karamchand ◽

Rory Leisegang ◽

Michael Schomaker ◽

Gary Maartens ◽

Lourens Walters ◽

...

Keyword(s):

Risk Factors ◽

Antiretroviral Therapy ◽

Reverse Transcriptase ◽

Transcriptase Inhibitor ◽

Incident Diabetes ◽

First Line ◽